Po-Lin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Po-Lin Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Tzu-Ting Kuo
Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
4 shared publications - Hsiao-Huang Chang
Department of Surgery, School of Medicine, Taipei Medical University, Taipei 110301, Taiwan
3 shared publications - I-Ming Chen
Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
3 shared publications Nai-Yuan Wu
Institute of Biomedical Informatics, College of Life Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan
3 shared publicationsChia-Cheng Kuo
Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
2 shared publicationsChiao-Po Hsu
School of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan
2 shared publications
Latest Publications
- Open Access
- 7 March 2023
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 18 (1) , 1-8
Left ventricular assist device exchange from HeartMate II to HeartMate 3 in an Asian patient—a case report and literature review
Pump exchange surgery of left ventricular assist device (LVAD) has been demonstrated in several studies; however, information for Asian patients was limited. A 63-year-old man underwent a pump upgrade from HeartMate II to HeartMate 3 for driveline damage through limited left anterior thoracotomy and lower partial sternotomy. He did not experience any hemodynamic adverse events or device malfunction during postoperative follow-ups of 12 months. We also reviewed all published cases with HeartMate II exchange to HeartMate 3. The case demonstrated that it was safe and feasible to perform HMII LVAD exchange to HM3 through a limited approach for Asian patients.
- 7 March 2023
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 18 (1) , 1-8
Open AccessLeft ventricular assist device exchange from HeartMate II to HeartMate 3 in an Asian patient—a case report and literature review
Pump exchange surgery of left ventricular assist device (LVAD) has been demonstrated in several studies; however, information for Asian patients was limited. A 63-year-old man underwent a pump upgrade from HeartMate II to HeartMate 3 for driveline damage through limited left anterior thoracotomy and lower partial sternotomy. He did not experience any hemodynamic adverse events or device malfunction during postoperative follow-ups of 12 months. We also reviewed all published cases with HeartMate II exchange to HeartMate 3. The case demonstrated that it was safe and feasible to perform HMII LVAD exchange to HM3 through a limited approach for Asian patients.
- Open Access
- 29 January 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (9) , 1748-1757
Aortic remodeling of the provisional extension to induce complete attachment technique in DeBakey type IIIb aortic dissection
- 29 January 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (9) , 1748-1757
Open AccessAortic remodeling of the provisional extension to induce complete attachment technique in DeBakey type IIIb aortic dissection
- Open Access
- 3 June 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (4) , 3418-3421
Intraoperative ECMO Assistance During TAVI for Aortic Insufficiency in an Asian Patient with LVAD Support
A 69-year-old male underwent concomitant left ventricular assist device (LVAD) implantation and aortic valve repair procedure for moderate aortic insufficiency (AI). Due to recurrence of symptomatic heart failure and post-repair AI deterioration from trivial to moderate-to-severe insufficiency 2 months later, transcatheter aortic valve implantation (TAVI) was arranged. During TAVI, intraoperative extracorporeal membrane oxygenation was used to maintain stable haemodynamics and to ensure a safe environment for prosthesis deployment. Postoperative 5 month follow-up revealed no AI and no paravalvular leakage.
- 3 June 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (4) , 3418-3421
Open AccessIntraoperative ECMO Assistance During TAVI for Aortic Insufficiency in an Asian Patient with LVAD Support
A 69-year-old male underwent concomitant left ventricular assist device (LVAD) implantation and aortic valve repair procedure for moderate aortic insufficiency (AI). Due to recurrence of symptomatic heart failure and post-repair AI deterioration from trivial to moderate-to-severe insufficiency 2 months later, transcatheter aortic valve implantation (TAVI) was arranged. During TAVI, intraoperative extracorporeal membrane oxygenation was used to maintain stable haemodynamics and to ensure a safe environment for prosthesis deployment. Postoperative 5 month follow-up revealed no AI and no paravalvular leakage.
- 21 December 2020
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 32 (1) , 97-105
Midterm result of custom-made iliac branch device for common iliac aneurysm with and without abdominal aortic aneurysm
OBJECTIVES: Although commercial iliac branch devices offer a new and valid endovascular approach to treating iliac aneurysm and effectively preserve antegrade flow of the internal iliac artery, their use may not be suited for all types of challenging anatomy, especially isolated common iliac artery aneurysm. Our custom-made iliac bifurcation device has a unique design and excludes both combined and isolated iliac branch aneurysm. This study validated the efficacy and safety of the custom device by comparing clinical outcomes between groups receiving commercial and custom devices. METHODS: Data of consecutive patients receiving iliac bifurcation device implantation for iliac aneurysm with or without concomitant endovascular repair for abdominal aortic aneurysm from January 2010 to May 2019 were reviewed. RESULTS: Iliac bifurcation device implantation with or without concomitant abdominal aortic aneurysm stent grafting was completed in 46 patients (commercial, n = 35; custom, n = 11). No significant differences were observed regarding postoperative complications, occlusion or endoleak. Comparisons of primary (80.8% vs 85.7%, P = 0.88) and secondary (86.5% vs 85.7%, P = 0.85) patency and freedom from reintervention (88.2% vs 100%, P = 0.33), all-cause mortality (78.6% vs 100%, P = 0.25) and aneurysm-related mortality (100% vs 100%, P = 1.00) also indicated no differences at a 5-year surveillance point. Furthermore, the iliac aneurysms of the groups displayed similar shrinkage 1 year after procedures. CONCLUSIONS: For iliac aneurysm, the novel custom-made iliac bifurcation device is an adaptable design not inferior to commercial devices with regard to postoperative complications, bridge occlusion, endoleak and short-term aneurysm remodelling. It provides an alternative for treatment, particularly when certain anatomic challenges are present. Clinical trial registration: 2018-07-050BC, 2017-01-023ACF.
- 21 December 2020
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 32 (1) , 97-105
Midterm result of custom-made iliac branch device for common iliac aneurysm with and without abdominal aortic aneurysm
OBJECTIVES: Although commercial iliac branch devices offer a new and valid endovascular approach to treating iliac aneurysm and effectively preserve antegrade flow of the internal iliac artery, their use may not be suited for all types of challenging anatomy, especially isolated common iliac artery aneurysm. Our custom-made iliac bifurcation device has a unique design and excludes both combined and isolated iliac branch aneurysm. This study validated the efficacy and safety of the custom device by comparing clinical outcomes between groups receiving commercial and custom devices. METHODS: Data of consecutive patients receiving iliac bifurcation device implantation for iliac aneurysm with or without concomitant endovascular repair for abdominal aortic aneurysm from January 2010 to May 2019 were reviewed. RESULTS: Iliac bifurcation device implantation with or without concomitant abdominal aortic aneurysm stent grafting was completed in 46 patients (commercial, n = 35; custom, n = 11). No significant differences were observed regarding postoperative complications, occlusion or endoleak. Comparisons of primary (80.8% vs 85.7%, P = 0.88) and secondary (86.5% vs 85.7%, P = 0.85) patency and freedom from reintervention (88.2% vs 100%, P = 0.33), all-cause mortality (78.6% vs 100%, P = 0.25) and aneurysm-related mortality (100% vs 100%, P = 1.00) also indicated no differences at a 5-year surveillance point. Furthermore, the iliac aneurysms of the groups displayed similar shrinkage 1 year after procedures. CONCLUSIONS: For iliac aneurysm, the novel custom-made iliac bifurcation device is an adaptable design not inferior to commercial devices with regard to postoperative complications, bridge occlusion, endoleak and short-term aneurysm remodelling. It provides an alternative for treatment, particularly when certain anatomic challenges are present. Clinical trial registration: 2018-07-050BC, 2017-01-023ACF.
- Open Access
- 1 March 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (11) , e0051
One-stage surgery for removal of intravascular leiomyomatosis extending to right ventricle
Intravascular leiomyomatosis (IVL) is a rare nonmalignant tumor that can be fatal if untreated. A 49-year-old nulliparous Asian woman who underwent hysterectomy and left salpingo-oophorectomy for multiple uterine leiomyomas 18 months prior presented complaining of intermittent palpitation and chest tightness for approximately 1 month. Echocardiography revealed a large mobile tumor mass extending from the inferior vena cava (IVC) to the right atrium that partially obstructed IVC flow and tricuspid inflow. Thoracicabdominopelvic computed tomography revealed a left adnexal tumor (4.8 × 2.5 cm) causing intravascular obstruction extending from the left internal iliac vein to the IVC, right atrium, and right ventricle. IVL with right heart involvement INTERVENTIONS:: Under cardiopulmonary bypass, a one-stage surgery combining sternotomy and laparotomy was performed. The tumor was approached and extracted via sternotomy, and tumor detachment and removal of residual tumors was accomplished via laparotomy. A firm, smooth, and regularly shape tumor 15.5 × 5.5 × 2.5 in size was completely removed and histopathologically confirmed as IVL. The patient tolerated the surgical procedure well and no postoperative complication was noted. We describe a one-stage surgical approach to completely remove an IVL extending to the right ventricle.
- 1 March 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (11) , e0051
Open AccessOne-stage surgery for removal of intravascular leiomyomatosis extending to right ventricle
Intravascular leiomyomatosis (IVL) is a rare nonmalignant tumor that can be fatal if untreated. A 49-year-old nulliparous Asian woman who underwent hysterectomy and left salpingo-oophorectomy for multiple uterine leiomyomas 18 months prior presented complaining of intermittent palpitation and chest tightness for approximately 1 month. Echocardiography revealed a large mobile tumor mass extending from the inferior vena cava (IVC) to the right atrium that partially obstructed IVC flow and tricuspid inflow. Thoracicabdominopelvic computed tomography revealed a left adnexal tumor (4.8 × 2.5 cm) causing intravascular obstruction extending from the left internal iliac vein to the IVC, right atrium, and right ventricle. IVL with right heart involvement INTERVENTIONS:: Under cardiopulmonary bypass, a one-stage surgery combining sternotomy and laparotomy was performed. The tumor was approached and extracted via sternotomy, and tumor detachment and removal of residual tumors was accomplished via laparotomy. A firm, smooth, and regularly shape tumor 15.5 × 5.5 × 2.5 in size was completely removed and histopathologically confirmed as IVL. The patient tolerated the surgical procedure well and no postoperative complication was noted. We describe a one-stage surgical approach to completely remove an IVL extending to the right ventricle.
- 22 July 2017
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 45, 270.e7-270.e11
Endografting under Assistance of Transapical Body Floss Through-and-Through Wiring Technique and Rapid Ventricular Pacing for an Ascending Aortic Tuberculous Pseudoaneurysm
- 22 July 2017
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 45, 270.e7-270.e11
Endografting under Assistance of Transapical Body Floss Through-and-Through Wiring Technique and Rapid Ventricular Pacing for an Ascending Aortic Tuberculous Pseudoaneurysm
- Open Access
- 10 May 2017
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 80 (8) , 482-486
Endovascular stenting for end-stage lung cancer patients with superior vena cava syndrome post first-line treatments – A single-center experience and literature review
Superior vena cava (SVC) syndrome comprises a group of signs and symptoms secondary to SVC obstruction. Obstruction occurs when venous return from the SVC to the right atrium is compromised, mostly by a growing malignancy compressing the SVC extrinsically.1, 2, 3, 4, 5 In the absence of adequate collaterals, the resulting elevated venous pressure in the upper body leads to edema of the head, neck, and upper extremities. Rarely, swelling of the larynx may cause life-threatening airway obstruction and cerebral edema, which can result in confusion and coma. While treatment of underlying malignant disease is paramount, it may be slow to alleviate the patient's discomfort. In some radiosensitive malignancies, radiotherapy may effectively reduce symptoms by reducing the tumor size,3, 6 but this process can take weeks to months and has a higher recurrence rate. The increasing technical and clinical success rate of SVC stenting makes it another option for salvage therapy after conventional radiochemotherapy has failed. In fact, Ganeshan et al. suggested that primary SVC stenting should be the first-line treatment to relieve the symptoms of SVC syndrome.4 The aim of the present study was to review our SVC stenting experience retrospectively in order to validate the safety, effectiveness, and outcomes of salvage and primary stenting for malignant SVC obstruction.
- 10 May 2017
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 80 (8) , 482-486
Open AccessEndovascular stenting for end-stage lung cancer patients with superior vena cava syndrome post first-line treatments – A single-center experience and literature review
Superior vena cava (SVC) syndrome comprises a group of signs and symptoms secondary to SVC obstruction. Obstruction occurs when venous return from the SVC to the right atrium is compromised, mostly by a growing malignancy compressing the SVC extrinsically.1, 2, 3, 4, 5 In the absence of adequate collaterals, the resulting elevated venous pressure in the upper body leads to edema of the head, neck, and upper extremities. Rarely, swelling of the larynx may cause life-threatening airway obstruction and cerebral edema, which can result in confusion and coma. While treatment of underlying malignant disease is paramount, it may be slow to alleviate the patient's discomfort. In some radiosensitive malignancies, radiotherapy may effectively reduce symptoms by reducing the tumor size,3, 6 but this process can take weeks to months and has a higher recurrence rate. The increasing technical and clinical success rate of SVC stenting makes it another option for salvage therapy after conventional radiochemotherapy has failed. In fact, Ganeshan et al. suggested that primary SVC stenting should be the first-line treatment to relieve the symptoms of SVC syndrome.4 The aim of the present study was to review our SVC stenting experience retrospectively in order to validate the safety, effectiveness, and outcomes of salvage and primary stenting for malignant SVC obstruction.
- 1 March 2005
- Published by Elsevier in Diamond and Related Materials
- Vol. 14 (3-7) , 804-809
Tube number density control of carbon nanotubes on anodic aluminum oxide template
- 1 March 2005
- Published by Elsevier in Diamond and Related Materials
- Vol. 14 (3-7) , 804-809
Tube number density control of carbon nanotubes on anodic aluminum oxide template